Mary Haak-Frendscho

This inventor holds 47 USPTO granted patents and 4 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Antibody Engineering. Top assignees: Amgen Fremont Inc., Takeda Pharmaceutical Company Limited, Promega Corporation. Active years: 1997-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary Haak-Frendscho. Retrieved from https://idiyas.com/inventor/mary-haak-frendscho

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 47 (Patent Applications = 4)

% Patents Active = 85.1

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 8)

Average Co-Inventor Count = 5.1

ph-index = 11

Forward Citations = 477(Granted Patents)

Location History:

Madison, WI (US) (1997 - 2004)
Newark, CA (US) (2004 - 2019)
San Francisco, CA (US) (2013 - 2022)

Company Filing History:

Takeda Pharmaceutical Company Limited

Warner-Lambert Company

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Anti-CD38

Antibodies

M-CSF

IL-1β

Tumor Necrosis Factor

Monocyte Chemo-attractant Protein-1

Pharmaceutical Compositions

Conjugated Antibodies

Inflammatory Diseases

Autoimmune Conditions

Cancer Treatments

Recombinant Proteins

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312411 - Anti-CD38 binding domains (2025-05-27),

2. 12209138 - Anti-CD38 antibodies (2025-01-28),

3. 11434304 - Anti-CD38 antibodies (2022-09-06),

4. 11414496 - Anti-CD38 binding domains (2022-08-16),

5. 10494444 - Anti-CD38 antibodies (2019-12-03),

6. 10336833 - Conjugated anti-CD38 antibodies (2019-07-02),

7. 10280219 - Antibodies to M-CSF (2019-05-07),

8. 10259872 - Antibodies to MAdCAM (2019-04-16),

9. 9790285 - Anti-CD38 antibodies (2017-10-17),

10. 9718883 - Antibodies to M-CSF (2017-08-01),

11. 9676869 - Conjugated anti-CD38 antibodies (2017-06-13),

12. 9328169 - Human antibodies that bind human MAdCAM (2016-05-03),

13. RE45847 - Antibodies to MAdCAM (2016-01-18),

14. 9206252 - Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof (2015-12-08),

15. 9102744 - Conjugated anti-CD38 antibodies (2015-08-11),

Certainly! Here is the article about inventor Mary Haak-Frendscho:

Title: Recognizing the Innovative Work of Mary Haak-Frendscho in Newark, CA

Introduction:

Mary Haak-Frendscho is a visionary inventor based in Newark, CA, with a profound passion for developing groundbreaking solutions in the field of biotechnology. With a remarkable portfolio of 45 patents to her name, she has made significant contributions to the scientific community.

Latest Patents:

Mary Haak-Frendscho's latest patents include pioneering inventions such as Anti-CD38 antibodies and Anti-CD38 binding domains. These inventions focus on developing isolated antibodies that bind to human CD38 and cynomolgus CD38, as well as providing therapeutic and diagnostic methods for treating conditions like multiple myeloma.

Career Highlights:

Throughout her career, Mary Haak-Frendscho has showcased her expertise while working at renowned companies such as Amgen Fremont Inc. and Promega Corporation. Her innovative spirit and dedication to advancing biotechnology have been instrumental in shaping the industry landscape.

Collaborations:

Mary Haak-Frendscho has collaborated closely with esteemed professionals in the field, including coworkers like Linda Masat and Gang Chen. Together, they have worked on cutting-edge projects that have pushed the boundaries of biotechnological research.

Conclusion:

In conclusion, Mary Haak-Frendscho stands as a beacon of innovation in Newark, CA, leaving a lasting impact on the biotechnology sector through her pioneering inventions and unwavering dedication to scientific advancement. Her prolific career serves as an inspiration to aspiring inventors and researchers around the world.

Profile summary based on public USPTO records.